18F-Fluoride PET/CT for detection of sacroiliitis in ankylosing spondylitis by Strobel, Klaus et al.
ORIGINAL ARTICLE
18F-Fluoride PET/CT for detection of sacroiliitis
in ankylosing spondylitis
Klaus Strobel & Dorothee R. Fischer & Giorgio Tamborrini & Diego Kyburz &
Katrin D. M. Stumpe & Rolf G. X. Hesselmann & A. Johayem &
Gustav K. von Schulthess & Beat A. Michel & Adrian Ciurea
Received: 3 October 2009 /Accepted: 29 March 2010 /Published online: 27 May 2010
# Springer-Verlag 2010
Abstract
Purpose The aim of this study was to evaluate the
performance of 18F-fluoride-PET/CT (PET/CT) for the
diagnosis of sacroiliac joint (SIJ) arthritis in patients with
active ankylosing spondylitis (AS).
Methods Included in the study were 15 patients with AS
according to the modified New York criteria (AS group)
and with active disease and 13 patients with mechanical
low back pain (MLBP; control group) who were investi-
gated with whole-body 18F-fluoride PET/CT. The ratio of
the uptake in the SIJ and that in the sacrum (SIJ/S) was
calculated for every joint.
Results The mean SIJ/S ratio of 30 quantified joints in the
AS group was 1.66 (range 1.10–3.07) with PET/CT, and
the mean SIJ/S ratio of 26 quantified joints in the MLBP
group was 1.12 (range 0.71–1.52). The area under the
receiver operating characteristic curve for SIJ arthritis was
0.84. With plain radiography as a the gold standard and
taking an SIJ/S ratio of >1.3 as the threshold, the
sensitivity, specificity and accuracy on a per patient basis
were 80%, 77% and 79%, respectively. On a per SIJ basis,
the greatest sensitivity (94%) was found in grade 3
sacroiliitis (n=16).
Conclusion Our results suggest that quantitative 18F-fluo-
ride PET/CT may play a role in the diagnosis of sacroiliitis
in active AS and is an alternative to conventional bone
scintigraphy in times of molybdenum shortage.
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Introduction
Ankylosing spondylitis (AS) is the prototype of a group of
chronic rheumatic diseases called spondyloarthritides (SpA)
that generally affect young people with an estimated
prevalence of 0.3–1.4% [1, 2]. The main clinical feature is
inflammatory back pain caused by sacroiliitis. Inflamma-
tion may extend to other locations of the spine as
spondylitis, spondylodiscitis or spondylarthritis, and ulti-
mately result in axial fusion, causing substantial functional
disability [3–5]. Peripheral arthritis and enthesitis, as well
as anterior uveitis, may also occur. Unequivocal radio-
graphic sacroiliitis of at least grade 2 bilaterally or grade 3
unilaterally, in addition to at least one clinical criterion, is
needed for the diagnosis of AS according to the modified
New York criteria [6]. Therefore, plain radiography is still
regarded as the imaging gold standard in the evaluation of
AS. By contrast, magnetic resonance imaging (MRI) is
considered to be the most sensitive imaging technique for
the detection of acute inflammation of the sacroiliac joints
(SIJ) [7–9]. It allows early diagnosis of SpA long before
postinflammatory chronic changes can be documented on
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plain radiographs [10, 11]. Quantitative analysis of sacro-
iliac biopsies has demonstrated a good correlation between
cellularity and MRI enhancement [12]. However, new bone
formation and fusion (ankylosis) in AS may be uncoupled
from inflammation, as exemplified by the failure so far of
immunosuppression via TNF-alpha inhibition to inhibit
radiographic disease progression [13, 14]. In this regard,
nuclear imaging techniques may detect increased bone
turnover not only during inflammation, but probably also
paralleling postinflammatory reparative changes at the
starting point of new bone formation [15].
Conventional scintigraphy with bone-seeking tracers such
as 99mTc-labelled diphosphonates have been used for decades
in patients with AS [16]. Recently, a systematic literature
review including 25 articles showed that scintigraphy
reaches sensitivities of 52% in patients with established AS
and 49.4% in patients with probable sacroiliitis [17]. With
the worldwide shortage of molybdenum [18, 19], the
increasing availability of positron emission tomography
(PET) scanners and the superior image quality, 18F-fluoride
PET/CT imaging has attracted increasing interest [20]. For
example, 18F-fluoride PET seems to be superior to planar
bone scintigraphy for the evaluation of metastatic disease
[21]. The aim of this study was to evaluate the performance
of 18F-fluoride PET/CT for the diagnosis of sacroiliitis in
patients with AS and to answer the question as to whether
this tracer can be used as an alternative in times of
molybdenum shortage. Patients with mechanical low back
pain (MLBP) served as a control group.
Materials and methods
Patient selection
The AS group comprised 15 patients with active AS who
fulfilled the modified New York criteria and were
recruited from a single rheumatology outpatient clinic.
The minimal disease activity required for inclusion was a
Bath ankylosing spondylitis disease activity index (BAS-
DAI) of at least 4 and/or spine pain of at least 4
(BASDAI item 2: second question of the BASDAI
instrument dealing with back pain) on a numerical rating
scale from 0 to 10 [22]. A BASDAI of 4 or higher is
considered to reflect a high disease activity [23]. C-
reactive protein (CRP) and erythrocyte sedimentation rate
(ESR) were measured in all patients at the time of
imaging.
The control group comprised 13 patients with non-
traumatic chronic MLBP for at least 3 months and a pain
intensity of at least 4 on a numerical rating scale ranging
from 0 to 10. MLBP was defined as back pain
exacerbating with exercise and improving with rest, as
well as with a duration of morning stiffness, if present,
of less than 15 minutes. The diagnoses in the MLBP
patients were obtained from the treating rheumatologist.
Patients with concomitant neoplastic or other inflamma-
tory rheumatic diseases were excluded. A plain radio-
graph of the pelvis or lumbar spine that ruled out
radiographic SIJ arthritis was available.
Patients were recruited for this study nonconsecutively
(“convenience sample”), provided that they met the inclusion
criteria, had been diagnosed as having AS orMLBP, and were
willing to participate. The local ethics committee approved the
protocol and all patients gave written informed consent.
Grading of SIJ on conventional radiographs
Conventional radiographs of the SIJ were available in all AS
patients and were classified by two experienced rheumatolo-
gists independently for sacroiliitis according to the radio-
graphic modified New York criteria [6] in consensus (0
normal; 1 changes suggestive of SIJ arthritis; 2 minimal
abnormality with small localized areas of erosions, sclerosis,
joint space widening or narrowing; 3 definitive abnormalities
with erosions, sclerosis, joint space widening or narrowing,
or partial ankylosis; 4 complete ankylosis).
18F-Fluoride PET/CT protocol
All the data were acquired on a combined PET/CT in-line
system (Discovery STE or Discovery Rx; GEHealth Systems,
Milwaukee, WI). In these dedicated systems a PET scanner
(GE Advance Nxi; GE Health Systems) is integrated with a
multislice helical CTscanner (Lightspeed 16, lightspeed VCT;
GE Health Systems) permitting the acquisition of coregistered
CT and PET images in one session. No special patient
preparation was needed before radiotracer administration.
Scanning was performed 30–45 min after intravenous
Fig. 1 Quantification of the SI joints with fluoride PET/CT showing
regions of interest over both SIJ and the sacrum
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injection of 100–150 MBq 18F-fluoride. Initially, a low-dose
CT scan was acquired covering the entire skeleton using the
following parameters: 40 mAs, 140 kV, 0.5 s per tube
rotation, slice thickness 4.25 mm, scan length 867 mm, data
acquisition time 22.5 s. The low-dose CT data were used for
correction of attenuation and localization of the lesions.
Immediately following the CT acquisition, a PET emission
scan was acquired with an acquisition time of 1.5 min
(scanner 1) or 2 min (scanner 2) per cradle position with a
one-slice overlap in 3-D mode. Thus, 12 or 13 cradle
positions starting from the head to the toes resulted in an
acquisition time of approximately 18–26 min. PET images
were reconstructed using a standard iterative algorithm
(OSEM) and sent to a AW workstation (GE Health Systems,
Milwaukee, WI) for further evaluation.
Quantification of SIJ with fluoride PET/CT
Quantification was performed in analogy to the method
established by conventional scintigraphy by drawing a
rectangular region of interest box over each SIJ and the
sacrum. The CT part of the PET/CT study helped to place
the box exactly and to exclude uptakes not related to the
joint. The maximal standard uptake value (SUV) in every
box was measured and the ratio of the SUV over the SIJ to
the SUV over the sacrum (SIJ/S ratio) was calculated for
every joint as shown in Fig. 1.
Statistical evaluation
Data were analysed using SPSS 15 for Windows (SPSS,
Chicago, IL). Receiver operating characteristic (ROC) curves
were used to evaluate the diagnostic performance of PET [24].
Results
Patient characteristics
The 15 patients with AS (11 men, 4 women) had a median
age of 46.6 years (range 31–64 years). The patients had
active disease with a mean (±SD) BASDAI of 5.8±1.5 and
a Bath ankylosing spondylitis functional index of 5.6±2.2.
The mean (±SD) CRP was 13.7±13.8 mg/l and the ESR
(first hour) was 22±18.7 mm.
The 13MLBP patients (5 men and 8 women) had a median
age of 51.5 years (range 32–74 years). These patients were
diagnosed as having osteoarthritis of the spine (n=8), lumbar
strain/sprain (n=2), fibromyalgia (n=2) and herniated lum-
Fig. 2 Box plots showing the performance of 18F-fluoride PET for
the diagnosis of SIJ arthritis using SIJ/S ratios for quantification
Fig. 3 ROC curve analysing the performance of 18F-fluoride PET/CT
for the diagnosis of sacroiliitis
Table 1 Sensitivity, specificity and accuracy of 18F-fluoride PET
quantification for the diagnosis of sacroiliitis in 15 patients with AS
and 13 patients with MLBP
Per patient analysis Per SIJ analysis
Sensitivity 80% (12/15) 70% (21/30)
Specificity 77% (10/13) 85% (22/26)
Accuracy 79% (22/28) 77% (43/56)
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bar disc (n=1). The mean (±SD) CRP in the control group
was 2.4±1.5 mg/l and the ESR (first hour) was 7.8±3.2 mm.
Radiographic SIJ grading in the AS group
In patients with AS SIJ grading on plan radiographs
showed grade 2 sacroiliitis in 10 joints (33%), grade 3 in
16 joints (53%) and grade 4 in 4 joints (13%). No joints
with grade 1 sacroiliitis were seen.
Quantitative 18F-fluoride PET/CT using the SIJ/S ratio
18F-Fluoride PET/CT quantification was feasible in all
patients. The mean SIJ/S ratio of 30 quantified joints was
1.66 (range 1.10–3.07) in the AS group. In the MLBP
group, the mean SIJ/S ratio of 26 quantified joints was 1.12
(range 0.71–1.52) (Fig. 2).
The area under the ROC curve for sacroiliitis was
0.84 (Fig. 3). Taking a SIJ/S ratio of >1.3 as a cut-off,
the sensitivity, specificity and accuracy on a per patient
basis were 80%, 77% and 79%, respectively, with
conventional radiology as the gold standard. In a per
joint basis equivalent values were 70%, 85% and 77%,
Fig. 4 A 49-year-old female
patient with ankylosing spondy-
litis. 18F-Fluoride PET/CT with
increased uptake (arrows) in
both SIJs with more uptake in
the left joint. MIP image (a),
axial PET (b), CT (c) and fused
PET/CT images (d) demonstrate
the morphologically severely al-
tered joints with sclerosis and
multiple erosions on both sides
(arrows)
Fig. 5 Box plots of SIJ/S ratios of 18F-fluoride PET/CT in relation to
conventional SIJ grading using plain radiographs in patients with AS
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respectively (Table 1). The sensitivity of PET imaging
was 40% in grade 2 sacroiliitis (n=10), 94% in grade 3
sacroiliitis (n=16) (Fig. 4) and 50% in grade 4 sacroiliitis
(n=4) (Fig. 5).
Discussion
To our knowledge, this is the first study evaluating the
performance of 18F-fluoride PET/CT for the diagnosis of
sacroiliitis in AS patients with active disease. Quantitative
PET/CT using the SIJ/S ratio with a cut-off of 1.3, as
established for conventional bone scintigraphy, is feasible.
The finding of an overall sensitivity of 80% for the
diagnosis of sacroiliitis may indicate the superiority of
18F-fluoride PET/CT in comparison to scintigraphy. For the
latter imaging method a sensitivity of 50–55% and a
specificity of about 80% was calculated following a recent
systematic literature review. The following characteristics
of the PET tracer might explain its superiority: rapid blood
clearance with high and quick bone uptake, resulting in a
better lesion-to-background ratio compared to 99mTc la-
belled phosphonates [20]. Additionally, PET devices are
superior to conventional gamma cameras with regard to
spatial resolution and sensitivity.
The lower sensitivity of PET in patients with grade 2
than in those with grade 3 sacroiliitis is intriguing, as we
would not expect the intensity of acute bone inflammation
to considerably differ between these two subgroups. We
assume that increased fluoride uptake might not only be a
consequence of inflammation but also of postinflammatory
repair osteoproliferation (greater areas of erosions and
sclerosis in joints with grade 3 sacroiliitis) [15]. The low
sensitivity of PET in patients with radiographic grade 4
sacroiliitis, as already demonstrated for scintigraphy [17],
might be explained by the fact that inflammation can no
longer be expected and osteoproliferation is already
complete in these fused joints (complete ankylosis). The
direct correlation between 18F-fluoride PET/CT, MRI and
histopathological examinations, which is the subject of
current research, might unravel this issue.
The CT part of the PET/CT imaging technique allows
the exact localization of the active lesion, as well as the
visualization of chronic changes including erosions, scle-
rosis and ankylosis. We intentionally ignored this informa-
tion in the present study and used the low-dose CT part
only for attenuation correction. We expect that combined
reading of PET and CT data would further increase the
sensitivity of this technique for the detection of sacroiliitis
not only in AS, but most importantly in patients with early
SpA. However, with regard to radiation exposure and
costs, PET/CT might only play a role in the routine
diagnosis of sacroiliitis if it is shown to provide a better
correlation with disease progression than the currently used
MRI [25].
We have tried to minimize exposure to radiation from
18F-fluoride PET/CT by lowering the applied 18F activity to
100–150 MBq per patient in comparison to 300–550 MBq
used in other institutions for the detection of bone
metastases. A low-dose protocol (40 mAs) was performed
for CT acquisition [20, 21, 26]. The estimated radiation
dose for the combined technique is similar to that of bone
scintigraphy (3–5 mSv).
We focused on evaluation of the SIJ in this pilot study.
In our experience 18F-fluoride PET/CT is also promising
for the evaluation of spine involvement as well as
peripheral arthritis and enthesitis during the same exami-
nation.
In conclusion, quantitative 18F-fluoride PET/CT may
play a role in the diagnosis of sacroiliitis in AS, and is a
possible alternative to conventional bone scintigraphy in
times of molybdenum shortage.
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